Skip to main content

Table 2 Comparison of variables between patients who were or were not reclassified as systemic sclerosis according to the 2013 ACR/EULAR classification criteria for systemic sclerosis

From: Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud’s phenomenon

Variables Patients reclassified as systemic sclerosis (N = 17) Patients not reclassified as systemic sclerosis (N = 47) P value P value *
Characteristics     
  Age (years old) 48.9 ± 12.4 51.7 ± 15.1 NS  
  Sex, female (N (%)) 17 (100) 41 (87.2) NS  
  Raynaud’s phenomenon duration (years) 3.4 ± 2.4 6.1 ± 9.0 NS  
The 2013 ACR/EULAR classification criteria score 10.5 ± 1.8 6.1 ± 1.7 <0.001 <0.001
Autoimmune disease accompanied (N (%)) 10 (58.8) 23 (48.9) NS  
  Sjögren syndrome 4 (23.5) 11 (223.4) NS  
  Systemic lupus erythematosus 4 (23.5) 4 (8.5) NS  
  Mixed connective tissue disease 2 (11.8) 3 (6.4) NS  
  Rheumatoid arthritis 2 (11.8) 1 (2.1) NS  
  Inflammatory myopathy 1 (5.9) 1 (2.1) NS  
Clinical manifestations (N (%))     
  Scleroderma (proximal) 0 (0) 0 (0) NS  
  Puffy finger 12 (70.6) 22 (46.8) NS  
  Sclerodactyly 6 (35.2) 1 (2.1) <0.001 <0.001
  Digital tip ulcer 2 (11.8) 0 (0) 0.017 0.034
  Fingertip pitting scar 0 (0) 0 (0) NS  
  Telangiectasia 5 (29.4) 2 (4.3) 0.004 0.008
  Abnormal nailfold capillaries 17 (100) 29 (61.7) 0.003 0.006
  Pulmonary arterial hypertension 0 (0) 1 (2.1) NS  
  Interstitial lung disease* 2 (11.8) 3 (6.4) NS  
Autoantibodies (N (%))     
  Antinuclear antibody (centromere) 9 (52.9) 16 (34.0) NS  
  Anti-centromere antibody 11 (64.7) 11 (23.4) 0.002 0.004
  Anti-Scl-70 antibody 0 (0) 2 (4.3) NS  
  1. Values are expressed as N (%) or mean ± standard deviation. P value* = Bonferroni-adjusted P value among variables with statistical significance. ACR, American College of Rheumatology; EULAR, The European League Against Rheumatism; NS, not significant.